Company intelligence / Profile preview

CorFlow Therapeutics

Ownership: Private
Development stage: Preclinical

Overview

Over 70 patients have been treated in the MOCA I first-in-human trial. The company’s technology has demonstrated feasibility for diagnosing and treating microvascular obstruction immediately after PCI. An international pivotal trial (“MOCA II IDE”) to confirm diagnostic accuracy and a randomized controlled therapy study are underway to support regulatory clearance.

Therapeutic areas: Cardiovascular
Modalities: Device (diagnostic and drug delivery platform)Drug delivery system (enables local administration of physician-specified agents)
Industry: Surgical Medical Devices

Partnerships

University of BernETH ZurichUniversity Hospital ZurichSwiss Innovation Agency Innosuisse funding academic collaborations

Beyond the preview

Go deeper on CorFlow Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CorFlow Therapeutics.

Explore the full profile